VNN Feed

Technicorum Holdings Launches Gennix Microlending Platform and $GNNX Token Sale on KingSwap and PancakeSwap.

A game-changing feature distinguishes Gennix from other DeFi lending and borrowing platforms. SINGAPORE — August 20, 2021 — Technicorum Holdings, an IT and service group specializing in Digital Assets and successful incubator of innovative DeFi and NFT project KingSwap, announced the official launch of the Gennix microlending platform today. Gennix microlending protocol aimed at reducing …

Technicorum Holdings Launches Gennix Microlending Platform and $GNNX Token Sale on KingSwap and PancakeSwap. Read More »

myLawyer launches its new MarketPlace website for consumers

San Francisco Bay Area, August 17, 2021 myLawyer launches the new website of the myLawyer MarketPlace. The myLawyer MarketPlace is an online marketplace dedicated to bringing together wine lovers from across the United States and boutique wineries from California. There are a large number of boutique wineries that produce very high-quality wines. Those wineries struggle …

myLawyer launches its new MarketPlace website for consumers Read More »

Seeking justice for Hamzeh Abu Shariah against the unjust system

Seeking justice for an innocent person under house arrest with false charges while the culprits roam free Arlington, Virginia (August 15, 2021) – Saddam Abu Shariah wants to point out a flaw in the justice system that has placed an innocent Jordanian American shop employee under house arrest. The arrest happened after 3 armed robbers …

Seeking justice for Hamzeh Abu Shariah against the unjust system Read More »

Soligenix: Phase III Trial Success Offers New Hope to Those Living with Rare Disease

Annual Incidence of Cutaneous T-cell Lymphoma is Six New Cases in One Million in the United States There is currently no FDA-approved first line treatment for CTCL Soligenix has the most advanced drug candidate for CTCL: HyBryte™ Soligenix has a cash runway of $29 million to fully fund marketing of its treatments  New York, NY …

Soligenix: Phase III Trial Success Offers New Hope to Those Living with Rare Disease Read More »